熱門資訊> 正文

Pacira聘请Molteni扩大EXPAREL在欧盟和英国的销售

2026-10-05 20:32

Pacira BioSciences(PCRX) 0

Pacira BioSciences (PCRX) signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K.
Under the agreement, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales in the licensed territories. Pacira will continue to manufacture EXPAREL, while Molteni will oversee regulatory, market access, and commercialization activities.
Molteni plans to launch EXPAREL sequentially in Italy, Germany, Austria, and Poland, with plans to seek approval in Switzerland; the first commercial sale is expected in 2027.

More on Pacira BioSciences

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform
Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira outlines $735M-$760M 2026 revenue guidance while targeting 160M EXPAREL covered lives
Pacira BioSciences Non-GAAP EPS of $0.75 beats by $0.10, revenue of $192.4M beats by $1.4M

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。